Shooting Cancer

21 12, 2023

Shooting Cancer Highlights – Monthly focus on regulatory status of new targeted therapies in oncology – November 2023

adlitterio663392023-12-21T10:08:16+01:00

28 06, 2023

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – April and May 2023

adlitterio663392023-06-28T10:28:18+02:00

1 04, 2023

Shooting Cancer Highlights – Monthly focus on regulatory status of new targeted therapies in oncology – February and March 2023

adlitterio663392023-06-28T10:54:57+02:00

2 03, 2023

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – January 2023

adlitterio663392023-03-02T10:17:25+01:00

11 01, 2023

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – November and December 2022

adlitterio663392023-01-11T12:15:44+01:00

15 11, 2022

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – October 2022
Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – October 2022

Nachrichten, Shooting Cancer

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – October 2022

adlitterio663392023-04-26T12:03:24+02:00

20 05, 2022

Monthly focus on regulatory status of new targeted therapies in oncology – April 2022

Diatech Pharmacogenetics2022-05-20T11:09:53+02:00

12 04, 2022

Monthly focus on regulatory status of new targeted therapies in oncology- March 2022

Diatech Pharmacogenetics2022-04-12T17:26:35+02:00

12 04, 2022

ALK rearrangements: a biomarker at the forefront of NSCLC treatment

Diatech Pharmacogenetics2022-04-12T12:18:29+02:00

17 03, 2022

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology February 2022

Diatech Pharmacogenetics2022-03-17T17:35:47+01:00